Aller au contenu principal
Accès ouvert déclaré 2025 article

International Severe Asthma Registry (ISAR): 2017–2024 Status and Progress Update

15Citations signalées, ce qui n’est pas une note de qualité
76Institutions déclarées
30Pays d’affiliation déclarés

Rattachement africain : mx, kr, ee, gb, us, bg, ie, sg, fr, be, ar, au, es, ec, de, pt, co, pl, se, br, ca, dk, gr, it, jp, kw, no, sa, tw, ae. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

The International Severe Asthma Registry (ISAR) was established in 2017 to advance the understanding of severe asthma and its management, thereby improving patient care worldwide. As the first global registry for adults with severe asthma, ISAR enabled individual registries to standardize and pool their data, creating a comprehensive, harmonized dataset with sufficient statistical power to address key research questions and knowledge gaps. Today, ISAR is the largest repository of real-world data on severe asthma, curating data on nearly 35,000 patients from 28 countries worldwide, and has become a leading contributor to severe asthma research. Research using ISAR data has provided valuable insights on the characteristics of severe asthma, its burdens and risk factors, real-world treatment effectiveness, and barriers to specialist care, which are collectively informing improved asthma management. Besides changing clinical thinking via research, ISAR aims to advance real-world practice through initiatives that improve registry data quality and severe asthma care. In 2024, ISAR refined essential research variables to enhance data quality and launched a web-based data acquisition and reporting system (QISAR), which integrates data collection with clinical consultations and enables longitudinal data tracking at patient, center, and population levels. Quality improvement priorities include collecting standardized data during consultations and tracking and optimizing patient journeys via QISAR and integrating primary/secondary care pathways to expedite specialist severe asthma management and facilitate clinical trial recruitment. ISAR envisions a future in which timely specialist referral and initiation of biologic therapy can obviate long-term systemic corticosteroid use and enable more patients to achieve remission.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
International Severe Asthma Registry (ISAR): 2017–2024 Status and Progress Update
Date Crossref
01/04/2025
Éditeur
The Korean Academy of Tuberculosis and Respiratory Diseases
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Hospital Médica SurThe Catholic University of Korea Seoul St. Mary's HospitalCatholic University of KoreaTartu University HospitalUniversity of TartuQueen's University BelfastAstraZeneca (United States)National Jewish HealthUniversity of Colorado DenverUniversity Hospital St. Ivan RilskiTrinity College DublinQueen Mary University of LondonBarts Health NHS TrustWilliam Harvey Research InstituteUniversity of MichiganLung InstituteNational University of SingaporeSingapore General HospitalDuke-NUS Medical SchoolCentre National de la Recherche ScientifiqueInsermPhysiologie et Médecine Expérimentale du Coeur et des MusclesCentre Hospitalier Universitaire de MontpellierUniversity of LiègeUniversity of PalermoFavaloro FoundationAlfred HealthMonash UniversityConcord Repatriation General HospitalMacquarie UniversityKing's College LondonMedical University of SofiaUniversidade de Santiago de CompostelaHospital Universitario Lucus AugustiUniversidad Espíritu SantoHumboldt-Universität zu BerlinFraunhofer Institute for Translational Medicine and PharmacologyBerlin Institute of Health at Charité - Universitätsmedizin BerlinCharité - Universitätsmedizin BerlinCentre for Health Technology and Services ResearchRoyal College of Surgeons in IrelandUniversidad de La SabanaFundación Neumológica ColombianaMedical University of LodzAstraZeneca (United Kingdom)Harefield HospitalAstraZeneca (Sweden)John Hunter HospitalHunter Medical Research InstituteSanta Casa HospitalUniversity of British ColumbiaVancouver Hospital and Health Sciences CentreVancouver General HospitalBispebjerg HospitalUniversité Paris CitéAssistance Publique – Hôpitaux de ParisRuhrlandklinikNational and Kapodistrian University of AthensUniversity of ManchesterHumanitas UniversityIRCCS Humanitas Research HospitalKindai University HospitalKuwait UniversityMinistry of HealthHaukeland University HospitalUniversity of BergenAlfaisal UniversityKing Fahd Medical CityHealth Research Institute of the Balearic IslandsNational Yang Ming Chiao Tung UniversityTaipei Veterans General HospitalRashid HospitalUniversity of SharjahRoyal Brompton HospitalObservational & Pragmatic Research InstituteUniversity of Aberdeen

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Asthma and respiratory diseasesChronic Obstructive Pulmonary Disease (COPD) Research

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.